This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study Comparing Premarin®/MPA, PREMPRO® and Provera® in Healthy Postmenopausal Women

This study has been completed.
MDS Pharma Services
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer Identifier:
First received: October 3, 2007
Last updated: June 17, 2010
Last verified: June 2010
The purpose of the study is to evaluate the safety and efficacy of new tablet formulations of Premarin®/medroxyprogesterone (MPA).

Condition Intervention Phase
Postmenopause Drug: Premarin/MPA Drug: Provera 10 mg Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: Open-Label, Single-Dose, Partially Randomized, 6-Period, 6-Treatment, Crossover Bioavailability Study of 3 Pilot Formulations of Premarin®/Medroxyprogesterone Acetate (MPA) Compared With Reference Formulations of Premarin®/MPA (PREMPRO®) and MPA Suspension (Provera®) in Healthy Postmenopausal Women

Resource links provided by NLM:

Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Primary Outcome Measures:
  • Plasma concentration data and pharmacokinetic (PK) parameters of MPA and Premarin® (estrone, equilin and MPA). [ Time Frame: 4 days ]

Estimated Enrollment: 30
Study Start Date: October 2007
Study Completion Date: December 2007
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1 Drug: Premarin/MPA
0.625 mg/2.5 mg X4
Drug: Premarin/MPA
0.625 mg/5 mg X 2
Active Comparator: 2 Drug: Provera 10 mg
2.5 mg of MPA, 4 tablets dissoved in water


Ages Eligible for Study:   35 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
  • Healthy postmenopausal women aged 35 to 70 years with spontaneous or surgical amenorrhea
  • BMI in the range of 18 to 35 kg/m2
  • History or presence of hypertension (>139 mm Hg systolic or >89 mm Hg diastolic)
  • History of drug allergy, particularly to conjugated estrogens (CE) or selective estrogen receptor modulators (SERMs)
  • Use of any prescription or investigational drug within 30 days before test article administration
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00543634

United States, Nebraska
Omaha, Nebraska, United States, 68154
Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
MDS Pharma Services
Study Director: Pfizer Call Center Wyeth is now a wholly owned subsidiary of Pfizer
  More Information

Responsible Party: Director, Clinical Trial Disclosure Group, Wyeth Identifier: NCT00543634     History of Changes
Other Study ID Numbers: 0713E1-1138
Study First Received: October 3, 2007
Last Updated: June 17, 2010

Additional relevant MeSH terms:
Medroxyprogesterone Acetate
Estrogens, Conjugated (USP)
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Contraceptive Agents, Male
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Contraceptives, Oral, Synthetic
Contraceptives, Oral processed this record on September 21, 2017